Celltrion, Inc. (068270.KS)
KRW 193100.0
(-3.06%)
KRW 193100.0
(-3.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 897.26 Billion KRW | 2.74% |
| 2022 | 801.91 Billion KRW | -12.58% |
| 2021 | 958.32 Billion KRW | 18.83% |
| 2020 | 835.87 Billion KRW | 54.0% |
| 2019 | 535.25 Billion KRW | 22.96% |
| 2018 | 447.55 Billion KRW | -25.64% |
| 2017 | 597.47 Billion KRW | 71.43% |
| 2016 | 331.51 Billion KRW | 5.53% |
| 2015 | 274.78 Billion KRW | 25.07% |
| 2014 | 264 Billion KRW | 33.5% |
| 2013 | 147.08 Billion KRW | -18.14% |
| 2012 | 241.12 Billion KRW | 18.96% |
| 2011 | 202.3 Billion KRW | 61.19% |
| 2010 | 124.79 Billion KRW | 53.96% |
| 2009 | 80.91 Billion KRW | 371.38% |
| 2008 | 36.08 Billion KRW | 173.48% |
| 2007 | 6.05 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 204.69 Billion KRW | 74.13% |
| 2024 Q1 | 147.03 Billion KRW | 107.41% |
| 2023 FY | - KRW | 2.74% |
| 2023 Q4 | 91.23 Billion KRW | -75.37% |
| 2023 Q1 | 260.4 Billion KRW | 126.75% |
| 2023 Q3 | 370.34 Billion KRW | 34.1% |
| 2023 Q2 | 276.17 Billion KRW | 6.05% |
| 2022 Q4 | 114.84 Billion KRW | -59.23% |
| 2022 Q3 | 281.67 Billion KRW | -1.19% |
| 2022 Q2 | 285.07 Billion KRW | 44.73% |
| 2022 Q1 | 196.96 Billion KRW | -24.18% |
| 2022 FY | - KRW | -12.58% |
| 2021 Q3 | 246.01 Billion KRW | 14.46% |
| 2021 Q1 | 261.63 Billion KRW | 63.85% |
| 2021 Q2 | 214.94 Billion KRW | -17.85% |
| 2021 FY | - KRW | 18.83% |
| 2021 Q4 | 259.77 Billion KRW | 5.59% |
| 2020 Q4 | 159.68 Billion KRW | -44.81% |
| 2020 FY | - KRW | 54.0% |
| 2020 Q1 | 163.7 Billion KRW | -1.44% |
| 2020 Q3 | 289.35 Billion KRW | 28.17% |
| 2020 Q2 | 225.75 Billion KRW | 37.91% |
| 2019 Q1 | 114.34 Billion KRW | 112.32% |
| 2019 FY | - KRW | 22.96% |
| 2019 Q3 | 143.33 Billion KRW | 16.72% |
| 2019 Q4 | 166.1 Billion KRW | 15.88% |
| 2019 Q2 | 122.79 Billion KRW | 7.4% |
| 2018 Q3 | 101.37 Billion KRW | -28.55% |
| 2018 Q4 | 53.85 Billion KRW | -46.88% |
| 2018 FY | - KRW | -25.64% |
| 2018 Q1 | 147.72 Billion KRW | -0.6% |
| 2018 Q2 | 141.87 Billion KRW | -3.96% |
| 2017 Q2 | 165.06 Billion KRW | 43.15% |
| 2017 FY | - KRW | 71.43% |
| 2017 Q4 | 148.6 Billion KRW | -10.86% |
| 2017 Q3 | 166.71 Billion KRW | 1.0% |
| 2017 Q1 | 115.3 Billion KRW | 23.69% |
| 2016 Q4 | 93.22 Billion KRW | 0.15% |
| 2016 Q3 | 93.08 Billion KRW | -4.84% |
| 2016 Q1 | 47.97 Billion KRW | 157.81% |
| 2016 FY | - KRW | 5.53% |
| 2016 Q2 | 97.82 Billion KRW | 103.91% |
| 2015 Q1 | 60.45 Billion KRW | 62.22% |
| 2015 Q3 | 94.65 Billion KRW | -6.56% |
| 2015 Q4 | 18.6 Billion KRW | -80.34% |
| 2015 Q2 | 101.29 Billion KRW | 67.56% |
| 2015 FY | - KRW | 25.07% |
| 2014 Q2 | 130.79 Billion KRW | 219.16% |
| 2014 FY | - KRW | 33.5% |
| 2014 Q4 | 37.26 Billion KRW | -33.21% |
| 2014 Q3 | 55.79 Billion KRW | -57.34% |
| 2014 Q1 | 40.98 Billion KRW | 184.95% |
| 2013 Q3 | 67.6 Billion KRW | 4.77% |
| 2013 FY | - KRW | -18.14% |
| 2013 Q4 | 14.38 Billion KRW | -78.73% |
| 2013 Q1 | 51.12 Billion KRW | -33.01% |
| 2013 Q2 | 64.52 Billion KRW | 26.21% |
| 2012 FY | - KRW | 18.96% |
| 2012 Q1 | 53.27 Billion KRW | 0.0% |
| 2012 Q3 | 56.87 Billion KRW | 29.03% |
| 2012 Q4 | 76.31 Billion KRW | 34.19% |
| 2012 Q2 | 44.07 Billion KRW | -17.27% |
| 2011 Q3 | 52.68 Billion KRW | 8.71% |
| 2011 Q2 | 48.46 Billion KRW | 7.4% |
| 2011 Q1 | 45.12 Billion KRW | 60.17% |
| 2011 FY | - KRW | 61.19% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 33.75 Billion KRW | 29.09% |
| 2010 Q1 | 26.15 Billion KRW | 24.77% |
| 2010 Q3 | 37.82 Billion KRW | 12.03% |
| 2010 Q4 | 28.17 Billion KRW | -25.5% |
| 2010 FY | - KRW | 53.96% |
| 2009 Q4 | 20.95 Billion KRW | 20.72% |
| 2009 FY | - KRW | 371.38% |
| 2009 Q3 | 17.36 Billion KRW | -43.37% |
| 2009 Q2 | 30.65 Billion KRW | 143.12% |
| 2009 Q1 | 12.61 Billion KRW | 794.02% |
| 2008 Q1 | 1.26 Billion KRW | 0.0% |
| 2008 Q3 | 15.93 Billion KRW | 1318.58% |
| 2008 Q4 | 1.41 Billion KRW | -91.15% |
| 2008 FY | - KRW | 173.48% |
| 2008 Q2 | -1.3 Billion KRW | -203.62% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q2 | 1.3 Billion KRW | -13.48% |
| 2007 Q1 | 1.51 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 1.71 Billion KRW | 31.17% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | -5627.063% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | -1242.374% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | -717.102% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | -10530.622% |
| Green Cross Corporation | 109.81 Billion KRW | -717.102% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 1508.603% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 44.042% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | -3839.342% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 4140.853% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 2989.959% |